Assertio’s latest offer represents a roughly 31% premium over an initial acquisition proposal. Elsewhere, Kyverna is readying a first-of-its-kind approval application and AC Immune is swapping CEOs.
An article from
News roundup
Assertio’s latest offer represents a roughly 31% premium over an initial acquisition proposal. Elsewhere, Kyverna is readying a first-of-its-kind approval application and AC Immune is swapping CEOs.
Published May 13, 2026
Getty Images
Five burning questions for Isomorphic after its mammoth $2B+ raise
Isomorphic Labs’ $2.1 Billion Fundraise Is The Biggest Bet Yet On AI Drug Discovery
Zydus Lifesciences acquires US pharma firm Assertio for $166 million
Zydus Lifesciences shares jump 6% on buyback buzz; co announces $166 mn Assertio acquisition
Alphabet’s Isomorphic Labs raises $2.1bn in Series B funding
Isomorphic Labs lands $2.1BN investment
Integrated CDO capabilities reduce early development complexity
A Series A, B and an IPO; Cabaletta reports CAR-T results
Astellas treatment offers new hope to a devastated rare disease community
In a bold move that positions Zydus at the forefront of the U.S. specialty oncology market, the Indian drug manufacturer has…
